EU Regulator Offers Boost to Cell Therapeutics Drug Application
Posted on: Thursday, 8 June 2006, 21:00 CDT
Cell Therapeutics has announced that a European Agency for the Evaluation of Medicinal Products panel has agreed in principle that a switch from superiority to non-inferiority endpoints in the company's phase III trials for Xyotax could be justified as a pathway to approval.
In addition, a shift in the non-inferiority margin may also be justified if the safety profile of Xyotax (paclitaxel poliglumex) is superior to comparators in terms of serious side effects and/or quality of life or use of rescue medications.
Cell Therapeutics (CTI) plans to file a marketing authorization application (MAA) in Europe in the first half of 2007 for Xyotax as a single agent for first-line treatment of non-small cell lung cancer (NSCLC) in ECOG performance status 2 patients.
"This is a very exciting outcome for CTI and more importantly for patients with lung cancer. We now have a clear route for potential approval in both the US and Europe with both regulatory agencies willing to accept the STELLAR trial results as supportive or, in the case of the EMEA, as pivotal," commented Dr James Bianco, president and CEO of CTI. "This could have a significant positive impact on both the time and cost for bringing this drug to market."
Source: Datamonitor
Related Articles
- National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness
- Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
- Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share
- CTI Closes Data Set for Endpoint Analysis in Phase III Lymphoma Trial
- Cell Therapeutics Names New President of European Operations
- Cell Therapeutics Files sBLA for Lymphoma Drug
- Cell Therapeutics Receives FDA Nod for Submission of Lymphoma Drug sBLA
- European Regulatory to Review CTI's Xyotax Marketing Application
- Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) With FDA for XYOTAX Lung Cancer Trial in Women
 |
 |
User Comments (0)
RSS Feeds